IBA SA : IBA Selected to Install New Proton Therapy Center in Charleroi, Belgium
20 Février 2017 - 07:00AM
IBA Selected to
Install New Proton Therapy Center in Charleroi, Belgium
New Proteus®One
installation to be dedicated to research and development in
collaboration with the Wallonia Region government and four leading
Belgian universities
Louvain-la-Neuve,
Belgium, February 20, 2017 - IBA (Ion Beam Applications SA),
the world's leading provider of proton therapy solutions for the
treatment of cancer, announces today that it has been selected as
the preferred vendor by four leading universities of Brussels
(ULB), Liège (Ulg), Mons (UMons) and Namur (UNamur), alongside the
Wallonia Region government, to install a Proteus®ONE*
solution, IBA's single-room compact proton therapy system, in
Charleroi, Belgium. IBA was selected following a comprehensive
European public tender process and expects to sign a final contract
in the coming weeks, after expiration of the applicable waiting
period.
The new center will be dedicated
primarily to the research and development of new proton therapy
applications and techniques in order to extend the range of proton
therapy used in the treatment of cancer. The center, which will
also treat patients, will be located in Charleroi and is expected
to be operational in 2020. The Wallonia Region will invest a total
of EUR 47 million in this research project, which will include the
IBA technology, research program, maintenance contract as well as
related equipment.
Olivier Legrain,
Chief Executive Officer of IBA commented: "We are delighted to
have been selected to build a proton therapy center dedicated to
R&D, demonstrating that Belgium has all the scientific,
clinical and technological expertise required to advance this
significant technology in the fight against cancer. Not only will
this research and development center enable IBA and the Belgian
universities to test and develop new generation technologies to
fight cancer, it will also develop and anchor industrial expertise
shared by a network of local companies. We are committed to
supporting these universities in providing high-quality cancer
treatment to more patients in Belgium."
- Ends -
About
IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The company is the worldwide
technology leader in the field of proton therapy, considered to be
the most advanced form of radiation therapy available today. IBA's
proton therapy solutions are flexible and adaptable, allowing
customers to choose from universal full-scale proton therapy
centers as well as compact, single room solutions. In addition, IBA
also has a radiation dosimetry business and develops particle
accelerators for the medical world and industry. Headquartered in
Belgium and employing about 1,500 people worldwide, IBA has
installed systems across the world.
IBA is listed on the pan-European
stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg
IBAB.BB). More information can be found at:
www.iba-worldwide.com
*Proteus®ONE is a brand
name of Proteus 235
For further
information, please contact:
IBA
Jean-Marc Bothy
Chief Strategy Officer
Soumya
Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas
Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com
For media and
investor enquiries:
Consilium
Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com
PR-ENG-ProteusONE
Charleroi
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024